Merry C, Puri P, Reen D J
Children's Research Centre, Our Lady's Hospital for Sick Children, Crumlin, Dublin, Ireland.
Pediatr Res. 1998 Aug;44(2):259-64. doi: 10.1203/00006450-199808000-00020.
We have investigated the role of actin polymerization in the defective polymorphonuclear neutrophil (PMN) chemotaxis of the human newborn, and its regulation by protein kinase C and by phosphatases 1 and 2A. Isolated PMNs from adult volunteers and healthy term newborns, i.e. umbilical cord blood, were studied. Chemotaxis was measured by a modified micropore filter assay, and actin polymerization was assessed by flow cytometry. Chemotaxis of newborn PMNs (median 18 microm, range 9-21 microm) was significantly reduced compared with adult PMNs (median 23 microm, range 17-34 microm) (p < 0.001). Coincubation with the protein kinase C inhibitor bisindolylmaleimide GF109203X, did not significantly alter chemotaxis, whereas coincubation with the phosphatase inhibitors calyculin A or okadaic acid caused parallel dose-dependent inhibition of chemotaxis in adult and newborn PMNs. Peak actin polymerization was reduced in newborn compared with adult PMNs in response to stimulation with formyl-methionyl-leucyl-phenylalanine and zymosan-activated serum, but was normal in response to phorbol myristate acetate. Prior incubation for 5 min with bisindolylmaleimide GF109203X, calyculin A, or okadaic acid caused no significant alterations in the actin polymerization response to stimulation with formyl-methionyl-leucyl-phenylalanine. We conclude that: 1) newborn PMNs have reduced actin polymerization in response to stimulation with chemotactic agents which act via cell surface receptors, but not with phorbol myristate acetate, which acts directly in the cytoplasm. This suggests that a defect in cell signal transduction may be an underlying factor in defective newborn PMN chemotaxis. 2) Phosphatase inhibitors strongly inhibit chemotaxis but not actin polymerization, therefore phosphatases 1 and 2A may be important regulators of PMN chemotaxis, but this regulation takes place either at a point distal to actin polymerization or via another pathway. 3) Similar results in adult and newborn PMNs suggest that this is not the site of the underlying defect in newborn PMN chemotaxis.
我们研究了肌动蛋白聚合在人类新生儿多形核中性粒细胞(PMN)趋化性缺陷中的作用,以及蛋白激酶C、磷酸酶1和2A对其的调节作用。研究对象为来自成年志愿者和健康足月儿(即脐带血)的分离PMN。趋化性通过改良微孔滤膜试验进行测量,肌动蛋白聚合通过流式细胞术进行评估。与成年PMN(中位数23微米,范围17 - 34微米)相比,新生儿PMN的趋化性(中位数18微米,范围9 - 21微米)显著降低(p < 0.001)。与蛋白激酶C抑制剂双吲哚马来酰亚胺GF109203X共同孵育,并未显著改变趋化性,而与磷酸酶抑制剂花萼海绵诱癌素A或冈田酸共同孵育,则会导致成年和新生儿PMN趋化性出现平行的剂量依赖性抑制。与成年PMN相比,新生儿PMN在受到甲酰甲硫氨酰亮氨酰苯丙氨酸和酵母聚糖激活血清刺激时,肌动蛋白聚合峰值降低,但在受到佛波酯肉豆蔻酸酯刺激时则正常。在用双吲哚马来酰亚胺GF109203X、花萼海绵诱癌素A或冈田酸预先孵育5分钟后,对甲酰甲硫氨酰亮氨酰苯丙氨酸刺激的肌动蛋白聚合反应未产生显著改变。我们得出以下结论:1)新生儿PMN在受到通过细胞表面受体起作用的趋化剂刺激时,肌动蛋白聚合减少,但在受到直接作用于细胞质的佛波酯肉豆蔻酸酯刺激时则不然。这表明细胞信号转导缺陷可能是新生儿PMN趋化性缺陷的潜在因素。2)磷酸酶抑制剂强烈抑制趋化性,但不抑制肌动蛋白聚合,因此磷酸酶1和2A可能是PMN趋化性的重要调节因子,但这种调节发生在肌动蛋白聚合的远端或通过另一条途径。3)成年和新生儿PMN的相似结果表明,这不是新生儿PMN趋化性潜在缺陷的部位。